companydata.dkcompanydata.dk

Ascendis Pharma Oncology Division A/S: Financial statements 2021

CVR: 41034076

Source: annual report 2021, Danish Business Authority

01/01/2021 – 31/12/2021

Ascendis Pharma Oncology Division A/S (CVR 41034076) has filed annual accounts for 2021. In 2021, the company reported a gross profit of EUR -46,676,711 and a net result of EUR -47,980,231 compared with EUR -36,079,781 the year before. Equity in the 2021 report amounted to EUR -76,108,650.

Gross Profit
EUR -46,676,711
Profit/Loss
EUR -47,980,231
Equity
EUR -76,108,650
Total Assets
EUR 5,608,137
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2021--46.7M EUR-48M EUR-76.1M EUR0
2020--35.7M EUR-36.1M EUR-28.1M EUR0

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like Ascendis Pharma Oncology Division A/S

Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.

Try the lead list generator

Events in 2021

Ascendis Pharma Oncology Division A/S: The 2020 annual report is outMar 29, 2021

Ascendis Pharma Oncology Division A/S has published its annual report for 2020. Gross profit came to DKK -35,705,202, and the net result was DKK -36,079,781.

About Ascendis Pharma Oncology Division A/S

Ascendis Pharma Oncology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -85,226,000 and a net result of EUR -110,131,000 compared with EUR -106,375,000 the year before. Equity in the 2025 report amounted to EUR -501,637,000.

Source: annual report 2025, Danish Business Authority

Other financial years